Overview

Dexamethasone as an Adjuvant to Bupivacaine in Suprazygomatic Maxillary Nerve Block

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Postoperative pain score, Faces, Legs, Activity, Cry, Consolability (FLACC) is the primary outcome. The secondary outcomes are the first-time requested analgesia, the number of children required analgesia, the total amount of analgesic requirements during first the 24 hours.
Phase:
N/A
Details
Lead Sponsor:
Assiut University
Treatments:
Bupivacaine
Dexamethasone